The Scientific World Journal / 2014 / Article / Fig 3

Research Article

Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells

Figure 3

HA-specific CD4+Thy1.1+ T cells from cervical lymph nodes of A20HA brain tumor-bearing mice show increased response to restimulation in vitro with MHC class II synthetic HA peptide. ((a), (b), (c)) Flow cytometry of CD4+Thy1.1+CD44+ T cells from cervical lymph nodes on day 2 after adoptive transfer. HA-specific CD4+Thy1.1+ T cells were injected i.v. into A20HA brain tumor-bearing mice 5 days after i.c. tumor inoculation (A20HA + T cells; dot plots in the upper row) and a tumor-free control group (T cells; dot plots in the middle row). A20HA brain tumor-bearing mice in the absence of HA-specific CD4+Thy1.1+ T cells represented a negative control (A20HA; dot plots in the lower row). Cervical lymph nodes were pooled and analyzed for CD4+Thy1.1+CD44+ T cells (a) before incubation (in vivo column; right upper quadrants) and ((b), (c)) after 72 h incubation in vitro in triplicates (b) without (in vitro column; right upper quadrants) and (c) with (in vitro column; right upper quadrants) HA peptide. Histograms under the dot plots show the level of CD44 expression in the gated populations of CD4+Thy-1.1+ T cells (shown in the right upper quadrants). Numbers above histograms indicate percent of gated CD4+Thy-1.1+ T cells in the designed dot plots (left numbers) and intensity of CD44 expression by these cells (right numbers). One representative experiment of equivalent two is shown.
(a) In vivo
(b) In vitro
(c) In vitro

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.